ClinicalTrials.gg
CompletedNCT05278676Updated Sep 14, 2023

A Single and Multiple Dose Study of Dotinurad in Chinese Healthy Participants

A Phase 1 interventional study of Dotinurad in Healthy Volunteers, sponsored by Eisai Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-14.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary purpose of this study is to evaluate the pharmacokinetics (PK) of dotinurad following single and multiple oral doses of dotinurad in Chinese healthy male and female participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy Chinese participants living in China.
  2. Non-smoking, male or female, age greater than or equal to (>=) 18 years and less than or equal to (\<=) 45 years old at the time of .
  3. Participants with serum uric acid level less than >=5.5 milligrams per decilitre (mg/dL) at Screening (Cohort B only).

Key Exclusion Criteria:

  1. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [β-hCG] or human chorionic gonadotropin [hCG] test). A separate baseline assessment of serum β-hCG (or hCG) or urine pregnancy test is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  2. Females of .
  3. illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing.
  4. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism.
  5. Any history of gastrointestinal surgery that may affect PK profiles of dotinurad, example, hepatectomy, nephrectomy, digestive organ resection at Screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Cohort A Single Dose: Dotinurad

    Participants will receive dotinurad 1 milligram (mg) (1\*1 mg tablet) as a single oral dose after 10-hour fasting on Day 1 in the morning.

    Drug: Dotinurad

  • Experimental
    Cohort B Multiple Dose: Dotinurad

    Participants will receive dotinurad 4 mg (2\*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning. A washout period of 3 days will be maintained after single dose on Day 1 and then participants will receive dotinurad 4 mg (2\*2 mg tablets) after 10-hour fasting from Day 4 to Day 10 once daily in the morning.

    Drug: Dotinurad

  • Experimental
    Cohort C Single Dose: Dotinurad

    Participants will receive dotinurad 10 mg (5\*2 mg tablets) as a single oral dose after 10-hour fasting on Day 1 in the morning.

    Drug: Dotinurad

Interventions

  • Dotinurad oral tablet.

    Also known as: FYU-981

06

What researchers measure

Primary outcomes

  1. Single-dose Part, Cmax: Maximum Observed Concentration for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  2. Single-dose Part, Tmax: Time at Which the Highest Drug Concentration Occurs for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  3. Single-dose Part, t1/2: Terminal Elimination Phase Half-life for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  4. Single-dose Part, AUC0-t: Area Under the Concentration-time Curve From Zero Time to Time of Last Quantifiable Concentration for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  5. Single-dose Part, AUC0-24h: Area Under the Concentration-time Curve From Zero Time to 24 hours for Dotinurad

    Time frame: Day 1: 0-24 hours post dose

  6. Single-dose Part, AUC0-inf: Area Under the Concentration-time Curve From Zero Time Extrapolated to Infinite Time for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  7. Single-dose Part, CL/F: Apparent Total Clearance Following Oral Administration for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  8. Single-dose Part, Vz/F: Apparent Volume of Distribution at Terminal Phase for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  9. Single-dose Part, kel: Elimination Rate Constant for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  10. Single-dose Part, MRT0-t: Mean Residence Time From Zero Time to Time of Last Quantifiable Concentration on Single Dose for Dotinurad

    Time frame: Day 1: 0-48 hours post dose

  11. Multiple-dose Part, Css,max: Maximum Observed Concentration at Steady State for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  12. Multiple-dose Part, Css,min: Minimum Observed Concentration at Steady State for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  13. Multiple-dose Part, Css,av: Average Steady-state Concentration for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  14. Multiple-dose Part, tss,max: Time at Which the Highest Drug Concentration Occurs at Steady State for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  15. Multiple-dose Part, t1/2: Terminal Elimination Phase Half-life for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  16. Multiple-dose Part, AUC0-τ: Area Under the Concentration-time Curve Over the Dosing Interval on Multiple Dosing for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  17. Multiple-dose Part, CLss/F: Apparent Total Clearance Following Oral Administration at Steady State for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  18. Multiple-dose Part, Vz/F: Apparent Volume of Distribution at Terminal Phase for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  19. Multiple-dose Part, kel: Elimination Rate Constant for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  20. Multiple-dose Part, MRT: Mean Residence Time for Dotinurad

    Time frame: Day 10: 0-72 hours post dose

  21. Multiple-dose Part, Rac(AUC0-24h): Accumulation Ratio for AUC(0-24h)

    Time frame: Day 10: 0-24 hours post dose

  22. Multiple-dose Part, Rac(Cmax): Accumulation Ratio for Cmax

    Time frame: Day 10: 0-72 hours post dose

  23. Multiple-dose Part, PTF: Peak-trough Fluctuation

    Time frame: Day 10: 0-72 hours post dose

07

Study locations

1 site
  • Shanghai Xuhui District Central Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Dec 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2022
First posted
Mar 14, 2022
StartActual
Jul 1, 2022
Primary completionActual
Dec 13, 2022
CompletionActual
Dec 13, 2022
Last update
Sep 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05278676
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Jul 1, 2022
Primary completion
Dec 13, 2022
Completion
Dec 13, 2022
Last update
Sep 14, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dotinurad

Start the discussion